Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2018-09-28 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Regulatory Filings
2018-09-28 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Glenmark Pharmaceuticals Limited regarding a proposed purchase of its own bonds (U.S.$200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities Due 2022). It details the appointment of dealer managers, the rationale for the transaction, the terms of the bond repurchase offer, and the indicative timetable for the transaction. The content focuses on a financing activity involving bond repurchase and cancellation, which is a capital structure change. There are no financial statements or detailed financial performance data, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a regulatory filing or certification, nor is it a voting result or management change announcement. It clearly relates to a capital/financing update about the company's debt management strategy. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6313 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2018-09-28 English
Updates
Capital/Financing Update Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the company's intention to buy back part of its FCC Bonds, specifying the amount, price, and dealer managers appointed. It references compliance with SEBI Listing Obligations and Disclosure Requirements. The content is an announcement of a financing activity related to bond buyback, not a full financial report or earnings release. The document length is short (2955 characters) and it is clearly an update on capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP).
2018-09-28 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) reporting the outcome of a Board Meeting held on September 28, 2018. The content focuses on the Board's approval of a repurchase (buyback) of foreign currency debt instruments (FCC Bonds and FCY Bonds). It authorizes an Operations Committee to execute the repurchase and related actions. The document is a notification of a corporate action related to financing activities, specifically a bond repurchase. It does not contain financial statements or detailed financial analysis, nor is it a full report or earnings release. The document is an update on capital structure changes and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 3676 characters, which is consistent with an announcement rather than a full report. Confidence is high given the clear focus on bond repurchase approval and related authorizations.
2018-09-28 English
Shareholders meeting
Regulatory Filings
2018-09-25 English
Board Meeting — Other business matters
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges and regulatory bodies informing about an upcoming Board Meeting to consider repurchase (buyback) of foreign currency debt instruments (FCC Bonds and FCY Bonds). It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including board meetings. The document does not contain financial statements or detailed financial data but is an announcement of a board meeting and potential capital action (debt buyback). It is not a full financial report, earnings release, or audit report. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes (debt repurchase). The document length is short (2531 characters), but it is not merely announcing a report publication; it is announcing a board meeting regarding financing decisions. Therefore, the classification is CAP with high confidence.
2018-09-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.